(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.14%) $83.50
(-0.20%) $2.47
(0.12%) $2 341.70
(0.43%) $29.74
(0.35%) $992.20
(0.05%) $0.931
(0.12%) $10.66
(0.03%) $0.791
(0.00%) $86.75
Live Chart Being Loaded With Signals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally...
Stats | |
---|---|
Today's Volume | 811 694 |
Average Volume | 885 025 |
Market Cap | 3.72B |
EPS | $-2.03 ( Q1 | 2024-05-03 ) |
Next earnings date | ( $-1.640 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.17 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0340 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-18 | Dunsire Deborah | Buy | 5 345 | Common Stock |
2024-06-18 | Dunsire Deborah | Buy | 9 900 | Stock Option (Right to Buy) |
2024-06-18 | Fust Matthew K | Buy | 5 345 | Common Stock |
2024-06-18 | Fust Matthew K | Buy | 9 900 | Stock Option (Right to Buy) |
2024-06-18 | Welch Daniel G | Buy | 5 345 | Common Stock |
INSIDER POWER |
---|
53.10 |
Last 99 transactions |
Buy: 996 554 | Sell: 324 656 |
Volume Correlation
Ultragenyx Pharmaceutical Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ultragenyx Pharmaceutical Correlation - Currency/Commodity
Ultragenyx Pharmaceutical Financials
Annual | 2023 |
Revenue: | $434.25M |
Gross Profit: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2023 |
Revenue: | $434.25M |
Gross Profit: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2022 |
Revenue: | $363.33M |
Gross Profit: | $335.01M (92.21 %) |
EPS: | $-10.12 |
FY | 2021 |
Revenue: | $351.41M |
Gross Profit: | $335.40M (95.44 %) |
EPS: | $-6.70 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators